Recent patenting activities in the discovery and development of vasopressin V2 receptor agonists.

about

The New England Research Institutes, Inc. (NERI) Nocturia Advisory Conference 2012: focus on outcomes of therapy.Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).

P2860

Q38077543-0FEB9FF6-9FC6-40A6-83B6-A07B40F53AC5 Q38380027-6BE45CFA-08D5-45B7-A616-A5F3F6F15C98

P2860

Recent patenting activities in the discovery and development of vasopressin V2 receptor agonists.

Item

http://www.wikidata.org/entity/Q38013154

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Recent patenting activities in ...... opressin V2 receptor agonists.

@en

type

Item

label

Recent patenting activities in ...... opressin V2 receptor agonists.

@en

prefLabel

Recent patenting activities in ...... opressin V2 receptor agonists.

@en

P1476

Recent patenting activities in ...... opressin V2 receptor agonists.

@en

P2093

Issei Tsukamoto

http://www.w3.org/2001/XMLSchema#string

P2860

Appearance of water channels in Xenopus oocytes expressing red cell CHIP28 protein

Cross-sectional study of nocturia in both sexes: analysis of a voluntary health screening project

Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia

Characterization of human platelet vasopressin receptors

Nocturia, nocturnal polyuria, and sleep quality in the elderly.

Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists.

Relation of nocturnal polyuria of the elderly to essential hypertension.

Optimization of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine-5-ylidene)acetamide derivatives as arginine vasopressin V2 receptor agonists and discussion of their binding modes.

Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.

Characterization of orally active nonpeptide vasopressin V(2) receptor agonist. Synthesis and biological evaluation of both the (5R)- and (5S)-enantioisomers of 2-[1-(2-Chloro-4-pyrrolidin-1-yl-benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin- 5-yl]-N-is

P304

579-586

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543776.2012.692778

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22630566

http://www.w3.org/2001/XMLSchema#string

P921

AVP

patent

Recent patenting activities in the discovery and development of vasopressin V2 receptor agonists.

about

P2860

P2860

Recent patenting activities in the discovery and development of vasopressin V2 receptor agonists.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921